Direct adsorption of lipoproteins (DALI) from whole blood: First long- term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia

Wiener Klinische Wochenschrift

Volumn 112, Issue 2, 2000, Pages 61-69

  Jansen, Martin ^a,b   Banyai, Susanne ^a   Schmaldienst, Sabine ^a   Goldammer, Andreas ^a   Rohac, Madeleine ^a   Hörl, Walter H ^a   Derfler, Kurt ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

DALI; Familial hypercholesterolaemia; LDL cholesterol; LDL apheresis; Lp(a)

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADSORPTION; ADULT; AGED; APHERESIS; ARTICLE; BLEEDING; BLOOD VOLUME; CLINICAL ARTICLE; DEVICE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON THERAPY; LIPOPROTEIN BLOOD LEVEL; MALE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; EQUIPMENT DESIGN; EVALUATION STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); LIPOPROTEINS, LDL; LONG-TERM CARE; MALE; MIDDLE AGED; PLASMAPHERESIS; PYRROLES; TREATMENT OUTCOME;

EID: 0034723431     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ballantyne ChM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto Jr AM (1997) Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 8: 354-361
2. Davignon J (1998) Advances in drug treatment of dyslipidemia: focus on atorvastatin. Can J Cardiol 14 [Suppl B]: 28B-38B
3. Gotto AMJr (1997) New directions in statin therapy. Clin Courier 16: 6-8
4. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin with that of lovastatin, pravastatin, simvastatin, and fluvastatin in patients with hypercholesterolemia: the CURVES study. Am J Cardiol 81: 582-587
5. Kroon AA, van Asten WNJC, Stalenhoef AFH (1996) Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 125: 945-954
6. Kroon AA, Aengevaeren WRW, van der Werf T, Uijen GJH, Reiber JHC, Bruschke AVG, Stalenhoef AFM (1996) LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93: 1826-1835
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Reccurrent Events Trial investigators. N Engl J Med 335: 1001-1009
8. Stein EA, Lane M, Laskarzewski P (1998) Comparison of statins in hypertriglyceridemia. Am J Cardiol 81: 66B-69B
9. Thompson GR, Maher VMG, Matthews S, Kitano Y, Neuwirth C, Shortt MB, Davies G, Rees A, Mir A, Prescott RJ, de Feyter P, Henderson A (1995) Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 345: 811-816
10. Wunsch H (1998) Issue of lower limit for LDL cholesterol unresolved. Lancet 351: 1257
11. Thompson GR, Lowenthal R, Myant NB (1975) Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet i: 1208-1211
12. Valbonesi M, Bigi L, Ferrari M, Florio G (1991) Cascade filtration for familial hypercholesterolemia. InI J Artif Organs 14: 751-753
13. Yamamoto A, Kawaguchi A, Harada-Shiba M, Tsushima M, Kojima S (1997) Apheresis technology for prevention and regression of atherosclerosis: an overview. Ther Apher 1: 233-241
14. Tatami R, Inoue N, Itoh H, Kishino B, Koga N, Nakashima Y, Nishide T, Okamura K, Saito Y, Teramoto T, Yashuki T, Yamamoto A, Goto V for the LARS Investigators (1992) Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 95: 1-13
15. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, Takegoshi T, Hokuriku FH-LDL-Apheresis Study Group (1998) Long-term efficacy of Low-Density-Lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 82: 1489-1495
16. Koga N (1997) The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. Ther Apher 1: 260-270
17. Gordon BR, Saal SD (1996) Current status of low density lipoprotein-apheresis for the therapy of severe hyperlipidemia. Curr Opin Lipidol 7: 381-384
18. Daida H, Yamaguchi H (1997) Clinical application and effectiveness of low-density lipoprotein apheresis in the treatment of coronary artery disease. Ther Apher 1: 253-254
19. Banyai S, Streicher J, Strobl W, Gabriel H, Gottsauner-Wolf M, Rohac M, Weidinger F, Hörl WH, Derfler K (1998) Therapeutic efficiency of Lp(a) reduction by LDL-immunoapheresis. Metabolism 47: 1058-1064
20. Jansen M, Gabriel H, Banyai S, Pidlich J, Weidinger F, Hörl WH, Derfler K (1996) Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient. Wien Klin Wochenschr 108: 425-431
21. Kostner K, Banyai S, Jansen M, Khoschsorur G, Hörl WH, Maurer G, Winkelhofer-Roob B, Derfler K (1999) Low density lipoprotein immunoapheresis does not increase plasma lipid peroxidation products in vivo. Clinica Chimica Acta 288: 21-30
22. Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisel K, Schwandt P (1993) Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42: 888-894
23. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A, Eisenhauer T, Grützmacher P, Keller C, Kettner U, Kleophas W, Köster W, Olbricht CJ, Richter WO, Seidel D, Group atH-S (1994) The HELP-LDL-apheresis multicenter study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease. Eur J Clin Invest 24: 724-732
24. Bambauer R, Olbricht CJ, Schoeppe E (1997) Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher 1: 242-248
25. Cattin L, Petrucco A, Cazzolato G, Bittolo G, Bittolo Bon G, Borelli V, Nardon E, Zabucchi G, Fonda M, Bordin P (1997) Low Density Lipoprotein-Apheresis decreases oxidized low density lipoproteins and monozyte adhesion to endothelial cells. ASAIO J 43: 209-213
26. Fadul JEM, Vessby B, Wikström B, Danielson BG (1997) Treatment of homozygous familial hypercholesterolemia with low density lipoprotein apheresis: a 4 year follow-up study. Artif Organs 21: 364-368
27. Knisel W, Pfohl M, Müller M, Besenthal I, di Niculo A, Voelker W, Risler T, Eggstein M (1994) Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins. Clin Invest 72: 660-668
28. Koizumi J, Koizumi I, Uno Y, Inazu A, Kajinami K, Haraki T, Yagi K, Kamon N, Miyamoto S, Takegoshi T, Mabuchi H, Takeda R, Tani N, Takeda S (1993) Reduction of lipoprotein (a) by LDL-apheresis using dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 100: 65-74
29. Pfohl M, Naoumova RP, Klass C, Knisel W, Jakober B, Risler T, Thompson GR (1994) Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 35: 1946-1955
30. Schaumann D, Welch-Wichary M, Voss A, Schmidt H, Olbricht CJ (1996) Prospective cross-over comparison of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolemia. Eur J Clin Invest 26: 1033-1038
31. Schiel R, Bambauer R, Müller U (1996) Low-density lipoprotein apheresis versus lipid lowering drugs in the treatment of severe hypercholesterolemia: four years' experience. Artif Organs 20: 318-323
32. Stefanutti C, Notarbartolo A, Colloridi V, Nigri A, Vivenzio A, Bertolini S, Bosco G, Berni A, Di Giacomo S, Mazzarella B (1997) LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5. Artif Organs 21: 1126-1127
33. Swoboda K, Derfler K, Koppensteiner R, Langer M, Pamberger P, Ehringer H, Druml W, Widhalm K (1993) Extracorporeal lipid elimination for treatment of gestational hyperlipidemic pancreatitis. Gastroenterology 104: 1527-1531
34. Bosch T, Schmidt B, Kleophas W, Gillen C, Otto V, Passlick-Deetjen J, Gurland HJ (1997) LDL-hemoperfusion - a new procedure for LDL apheresis: First clinical application of an LDL adsorber compatible with human whole blood. Int J Artif Organs 21: 977-981
35. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W (1997) LDL hemoperfusion - a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 21: 1060-1065
36. Derfler K, Druml W (1998) A novel LDL-apheresis device for removal of atherogenic lipoproteins from the whole blood. Eur J Clin Invest 28: 1003-1005
37. Dräger LJ, Julius U, Kraenzle K, Schaper J, Toepfer M, Zygan K, Otto V, Steinhagen-Thiessen E (1998) DALI-The first human whole blood LDL- and Lp(a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 28: 994-1002
38. Nadler SB, Hidalgo JU, Bloch T (1962) Prediction of blood volume in normal human adults. Surgery 51: 224-232
39. Bosch Th, Thiery J, Gurland HJ, Seidel D (1993) Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and hemodialysis in patients with hypercholesterolemia and end-stage renal failure. Nephrol Dial Transplant 8: 1350-1358
40. Inoue K, Bambauer R (1998) Evaluation of microparticles released from an adsorber used for low density lipoprotein apheresis. ASAIO J 44: M470-M474
41. Ramlow W et al (2000) Particle release in extracorporal LDL Lowering therapies. Artif Organs (accepted for publication)
42. Leong ASY, Disney APS, Gove DW (1981) Refractile particles in liver of hemodialysis patients. Lancet i: 889-890